Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...

On December 24, President Ilham Aliyev and First Lady Mehriban Aliyeva visited several liberated areas, a visit that carried ...

Starting an incretin receptor agonist -- especially tirzepatide (Mounjaro, Zepbound) -- was associated with reduced risks of ...

The prospective data indicate that clinicians should be aggressive with lipid-lowering therapies in these patients, experts say.

Nemolizumab rapidly relieves itch and sleep disturbance among patients with moderate-to-severe atopic dermatitis (AD) and ...

Oral micronutrient supplementation showed no benefit on geographic atrophy lesion growth among a patient group from the OAKS and DERBY trials, according to a speaker ...

In a subgroup analysis of patients with polypoidal choroidal vasculopathy, aflibercept 8 mg achieved similar vision gains to ...

Nektar Therapeutics is advancing Rezpeg in atopic dermatitis and alopecia areata. Click here for key insights on NKTR's ...

Clinicians from Fox Chase Cancer Center at Temple University Health share their highlights from the Society of Urologic ...

Natera (NTRA) announced the publication of findings from the randomized, phase III CALGB/SWOG 80702 study in JAMA Oncology. This publication ...

Once-weekly tirzepatide is associated with clinically relevant reductions in SUA levels over 72 weeks, largely driven by substantial weight loss.

Office and ambulatory BP improved, with minimal side effects, although some say edema needs to be watched carefully.